Table SII. Descriptive statistics of clinical scores, anti-desmoglein-1 (anti-DSG-1) autoantibodies and anti-DSG-3 autoantibodies for each subgroup of patients at baseline, month 6 and month 12

<table>
<thead>
<tr>
<th>Time-point</th>
<th>Clinical characteristics</th>
<th>Subgroup A ( (n=7) ) Median (min–max)</th>
<th>Subgroup B ( (n=11) ) Median (min–max)</th>
<th>Subgroup C ( (n=17) ) Median (min–max)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>ABSIS (Total)</td>
<td>13.0 (1.5–94.5)</td>
<td>19.0 (9.5–54.0)</td>
<td>39.5 (11.5–168.0)</td>
</tr>
<tr>
<td></td>
<td>Skin involvement score</td>
<td>13.0 (1.5–94.5)</td>
<td>0.0 (0.0–0.0)</td>
<td>24.0 (4.5–112.0)</td>
</tr>
<tr>
<td></td>
<td>Mucosal extent score</td>
<td>0.0 (0.0–0.0)</td>
<td>3.0 (1.0–10.0)</td>
<td>3.0 (1.0–11.0)</td>
</tr>
<tr>
<td></td>
<td>Mucosal severity score</td>
<td>0.0 (0.0–0.0)</td>
<td>16.0 (8.5–44.0)</td>
<td>16.0 (4.5–45.0)</td>
</tr>
<tr>
<td></td>
<td>PDAI (Total)</td>
<td>10.0 (3.0–51.0)</td>
<td>20.0 (2.0–32.0)</td>
<td>25.0 (9.0–158.0)</td>
</tr>
<tr>
<td></td>
<td>Cutaneous lesions score</td>
<td>10.0 (3.0–51.0)</td>
<td>0.0 (0.0–0.0)</td>
<td>13.0 (3.0–79.0)</td>
</tr>
<tr>
<td></td>
<td>Mucous membranes score</td>
<td>0.0 (0.0–0.0)</td>
<td>20.0 (2.0–32.0)</td>
<td>4.0 (2.0–79.0)</td>
</tr>
<tr>
<td></td>
<td>DSG-1</td>
<td>142.6 (31.3–214.6)</td>
<td>6.5 (3.5–22.2)</td>
<td>115.4 (3.8–204.7)</td>
</tr>
<tr>
<td></td>
<td>DSG-3</td>
<td>6.1 (2.1–143.9)</td>
<td>154.7 (23.3–192.7)</td>
<td>133.2 (21.2–181.3)</td>
</tr>
<tr>
<td>Month 6</td>
<td>ABSIS (Total)</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–12.0)</td>
<td>0.0 (0.0–75.0)</td>
</tr>
<tr>
<td></td>
<td>Skin involvement score</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–48.0)</td>
</tr>
<tr>
<td></td>
<td>Mucosal extent score</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–3.0)</td>
<td>0.0 (0.0–5.0)</td>
</tr>
<tr>
<td></td>
<td>Mucosal severity score</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–9.0)</td>
<td>0.0 (0.0–22.0)</td>
</tr>
<tr>
<td></td>
<td>PDAI (Total)</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–6.0)</td>
<td>0.0 (0.0–34.0)</td>
</tr>
<tr>
<td></td>
<td>Cutaneous lesions score</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–27.0)</td>
</tr>
<tr>
<td></td>
<td>Mucous membranes score</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–6.0)</td>
<td>0.0 (0.0–7.0)</td>
</tr>
<tr>
<td></td>
<td>DSG-1</td>
<td>10.5 (4.3–16.9)</td>
<td>4.8 (3.2–10.5)</td>
<td>8.9 (0.7–134.8)</td>
</tr>
<tr>
<td></td>
<td>DSG-3</td>
<td>6.5 (1.6–13.9)</td>
<td>81.4 (4.7–159.0)</td>
<td>14.5 (2.1–170.2)</td>
</tr>
<tr>
<td>Month 12</td>
<td>ABSIS (Total)</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–37.0)</td>
<td>0.0 (0.0–30.5)</td>
</tr>
<tr>
<td></td>
<td>Skin involvement score</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–10.5)</td>
</tr>
<tr>
<td></td>
<td>Mucosal extent score</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–7.0)</td>
<td>0.0 (0.0–3.0)</td>
</tr>
<tr>
<td></td>
<td>Mucosal severity score</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–30.0)</td>
<td>0.0 (0.0–17.0)</td>
</tr>
<tr>
<td></td>
<td>PDAI (Total)</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–30.0)</td>
<td>0.0 (0.0–15.0)</td>
</tr>
<tr>
<td></td>
<td>Cutaneous lesions score</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–12.0)</td>
</tr>
<tr>
<td></td>
<td>Mucous membranes score</td>
<td>0.0 (0.0–0.0)</td>
<td>0.0 (0.0–30.0)</td>
<td>0.0 (0.0–11.0)</td>
</tr>
<tr>
<td></td>
<td>DSG-1</td>
<td>5.5 (3.1–8.9)</td>
<td>4.7 (0.7–15.3)</td>
<td>6.9 (0.5–33.8)</td>
</tr>
<tr>
<td></td>
<td>DSG-3</td>
<td>4.8 (1.1–7.1)</td>
<td>51.6 (3.6–144.6)</td>
<td>6.7 (1.1–144.5)</td>
</tr>
</tbody>
</table>